Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Saved in:
| Title: | Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. |
|---|---|
| Authors: | Saxena A; Division of Rheumatology, New York University School of Medicine, New York, New York., Ginzler EM; Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York., Gibson K; Department of Medicine, UNC Kidney Center, Chapel Hill, North Carolina., Satirapoj B; Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand., Santillán AEZ; Instituto de Ginecología y Reproducción, Lima, Peru., Levchenko O; Odessa Regional Clinical Hospital, Oblast, Ukraine., Navarra S; Rheumatology Section, University of Santo Tomas, Manila and St Luke's Medical Center, Quezon City, Philippines., Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Hokkaido University, Sapporo, Japan., Yasuda S; Department of Rheumatology, Graduate School of Medical and Dental Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan., Chavez-Perez NN; Unidad de Reumatología, Hospital General de Enfermedades, Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala., Arriens C; Department of Arthritis & Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City., Parikh SV; Department of Nephrology, The Ohio State University Wexner Medical Center, Columbus., Caster DJ; Department of Medicine, Division of Nephrology and Hypertension, University of Louisville School of Medicine, Louisville, Kentucky., Birardi V; Medical Affairs, Aurinia Pharmaceuticals, Edmonton, Alberta, Canada., Randhawa S; Dianthus Therapeutics, Waltham, Massachusetts., Lisk L; Clinical Development, Aurinia Pharmaceuticals, Edmonton, Alberta, Canada., Huizinga RB; Reformation Consulting Services, North Saanich, British Columbia, Canada; Research and Development, Aurinia Pharmaceuticals, Edmonton, Alberta, Canada., Teng YKO; Center for Expertise on Lupus-, Vasculitis- and Complement-mediated Systemic Autoimmune Diseases, Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands. |
| Source: | Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2024 Jan; Vol. 76 (1), pp. 59-67. Date of Electronic Publication: 2023 Sep 15. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
